anti-Advanced Glycosylation End Product-Specific Receptor (AGER) Antikörper

Bezeichnung:
anti-Advanced Glycosylation End Product-Specific Receptor Antikörper (AGER)
Auf www.antikoerper-online.de finden Sie aktuell 308 Advanced Glycosylation End Product-Specific Receptor (AGER) Antikörper von 30 unterschiedlichen Herstellern. Zusätzlich bieten wir Ihnen Advanced Glycosylation End Product-Specific Receptor Kits (81) und Advanced Glycosylation End Product-Specific Receptor Proteine (40) und viele weitere Produktgruppen zu diesem Protein an. Insgesamt sind aktuell 446 Advanced Glycosylation End Product-Specific Receptor Produkte verfügbar.
Synonyme:
AGER, RAGE
Alle Antikörper anzeigen Gen GeneID UniProt
AGER 177 Q15109
AGER 11596  
AGER 81722  

Alle Spezies anzeigen

Weitere Synonyme anzeigen

Meistgesuchte Reaktivitäten zu anti-Advanced Glycosylation End Product-Specific Receptor (AGER) Antikörper

Wählen Sie die Spezies und Applikation aus

anti-Human Antikörper:

anti-Mouse (Murine) Antikörper:

anti-Rat (Rattus) Antikörper:

Alle verfügbaren anti-Advanced Glycosylation End Product-Specific Receptor Antikörper

Sie gelangen zu unserer vorgefilterten Suche.

Am meisten referenzierte anti-Advanced Glycosylation End Product-Specific Receptor Antikörper

  1. Rat (Rattus) Polyclonal AGER Primary Antibody für FACS, IF (p) - ABIN725900 : Huang, Yao, Zhang, Dong, Yu, Sheng: The effect of high-mobility group box 1 protein on activity of regulatory T cells after thermal injury in rats. in Shock (Augusta, Ga.) 2009 (PubMed)
    Zeige alle 5 Referenzen für 725900

  2. Human Polyclonal AGER Primary Antibody für IF, IHC (p) - ABIN1108826 : Bierhaus, Haslbeck, Humpert, Liliensiek, Dehmer, Morcos, Sayed, Andrassy, Schiekofer, Schneider, Schulz, Heuss, Neundörfer, Dierl, Huber, Tritschler, Schmidt, Schwaninger, Haering, Schleicher, Kasper et al.: Loss of pain perception in diabetes is dependent on a receptor of the immunoglobulin superfamily. ... in The Journal of clinical investigation 2004 (PubMed)
    Zeige alle 4 Referenzen für 1108826

  3. Human Polyclonal AGER Primary Antibody für EIA, IHC (p) - ABIN357685 : Schlueter, Hauke, Flohr, Rogalla, Bullerdiek: Tissue-specific expression patterns of the RAGE receptor and its soluble forms--a result of regulated alternative splicing? in Biochimica et biophysica acta 2003 (PubMed)
    Zeige alle 3 Referenzen für 357685

  4. Cow (Bovine) Polyclonal AGER Primary Antibody für WB - ABIN2786877 : Luo, Saiardi, Nagata, Ye, Yu, Jung, Luo, Jain, Sawa, Snyder: GRAB: a physiologic guanine nucleotide exchange factor for Rab3A, which interacts with inositol hexakisphosphate kinase. in Neuron 2001 (PubMed)
    Zeige alle 2 Referenzen für 2786877

  5. Human Polyclonal AGER Primary Antibody für EIA, IHC (p) - ABIN359696 : Miyata, Akashi, Nishida: Molecular cloning and characterization of a novel member of the MAP kinase superfamily. in Genes to cells : devoted to molecular & cellular mechanisms 1999 (PubMed)
    Zeige alle 2 Referenzen für 359696

  6. Human Polyclonal AGER Primary Antibody für IF, WB - ABIN390897 : Peng, Lu, Wang, Yan, Chen, Zhang, Zhang, Shen: RAGE gene polymorphisms are associated with circulating levels of endogenous secretory RAGE but not with coronary artery disease in Chinese patients with type 2 diabetes mellitus. in Archives of medical research 2009 (PubMed)

  7. Human Polyclonal AGER Primary Antibody für FACS, IHC (p) - ABIN651054 : Rojas, Figueroa, Morales: Fueling inflammation at tumor microenvironment: the role of multiligand/RAGE axis. in Carcinogenesis 2010 (PubMed)

  8. Cow (Bovine) Polyclonal AGER Primary Antibody für WB - ABIN2776831 : Galichet, Weibel, Heizmann: Calcium-regulated intramembrane proteolysis of the RAGE receptor. in Biochemical and biophysical research communications 2008 (PubMed)

  9. Human Polyclonal AGER Primary Antibody für IHC, WB - ABIN2776917 : Lieuw-a-Fa, Schalkwijk, Engelse, van Hinsbergh: Interaction of Nepsilon(carboxymethyl)lysine- and methylglyoxal-modified albumin with endothelial cells and macrophages. Splice variants of RAGE may limit the responsiveness of human endothelial cells to AGEs. in Thrombosis and haemostasis 2006 (PubMed)

Weitere Antikörper gegen Advanced Glycosylation End Product-Specific Receptor Interaktionspartner

Human Advanced Glycosylation End Product-Specific Receptor (AGER) Interaktionspartner

  1. There was no significant difference in plasma levels of sRAGE or HMGB1 (zeige HMGB1 Antikörper) between pAPS (zeige PAPSS1 Antikörper) patients and HCs (zeige HLCS Antikörper). Plasma levels of sRAGE/HMGB1 (zeige HMGB1 Antikörper) could not be utilized to differentiate between APA (zeige ENPEP Antikörper)+SLE and APS (zeige SH2B2 Antikörper)+SLE patients

  2. Ligand-induced association of RAGE homodimers on the cell surface increases the molecular dimension of the receptor, recruiting DIAPH1 (zeige DIAPH1 Antikörper) and activating signaling pathways.

  3. AGER polymorphisms showed no statistically significant difference between patients with primary open-angle glaucoma and healthy controls.

  4. Our findings demonstrate how RAGE-PR3 interactions between human prostate cancer cells and the bone marrow microenvironment mediate bone metastasis during prostate cancer progression

  5. The severity of acute respiratory distress syndrome in preterm infants seemed to be associated with the plasma level of sRAGE and AQP5 (zeige AQP5 Antikörper): the more severe the disease, the higher the plasma level of sRAGE and AQP5 (zeige AQP5 Antikörper)

  6. Advanced glycation end products are capable of inducing VEGF (zeige VEGFA Antikörper) production and inflammatory responses via RAGE-NF-kappaB (zeige NFKB1 Antikörper) pathway activation in synoviocytes.

  7. Atrial tissue expression of RAGE was significantly associated with atrial fibrosis in patients with mitral valve disease.

  8. RAGE drives tumor progression and metastasis through distinct tumor cell-intrinsic and -extrinsic mechanisms, and may represent a novel and therapeutically viable approach for treating metastatic cancers.

  9. these studies suggest that expression of RAGE in T cells of patients at risk for type 1 diabetes progressing to disease predates dysglycemia

  10. These studies confirm that intranasal insulin (zeige INS Antikörper) improves indexes of experimental DPN but indicates that females with DPN may differ in their underlying phenotype. RN mice had partial but incomplete protection from underlying DPN and lesser impacts from insulin (zeige INS Antikörper).

Cow (Bovine) Advanced Glycosylation End Product-Specific Receptor (AGER) Interaktionspartner

  1. Our results suggested that the increased RAGE expression in inflammatory circumstances and interaction with AGEs are risk factors in decreasing of aggrecan (zeige ACAN Antikörper) content in nucleus pulposus.

Mouse (Murine) Advanced Glycosylation End Product-Specific Receptor (AGER) Interaktionspartner

  1. perturbation of Bone marrow mesenchymal stromal cells in diabetes mellitus could be partially explained by chronic RAGE signaling.

  2. RAGE mediates inflammation that contributes to lung damage, in cigarette smoke-induced lung pathology.

  3. Ager deletion enhances ischemic muscle inflammation, angiogenesis, and blood flow recovery in diabetic mice.

  4. HMGB1 (zeige HMGB1 Antikörper) neither exerts influence on cardiac remodeling by binding to RAGE nor induces apoptosis of cardiomyocytes under physiological condition

  5. Our results indicate that lack of RAGE has no significant impact on septic arthritis. However, RAGE-/- mice had significantly higher BMD (zeige BEST1 Antikörper) compared to WT mice, which coincided with lower IL-17A (zeige IL17A Antikörper) in RAGE-/- mice. In sepsis, RAGE deficiency impairs bacterial kidney clearance.

  6. SAA (zeige SAA1 Antikörper) is a potential new uremic toxin involved in uremia-related atherosclerosis through interaction with RAGE.

  7. that selective RAGE regulation reflects a self-protective mechanism to maintain low levels of RAGE ligands

  8. Data show that receptor for advanced glycation end products (RAGE) impairs collateral growth in a diabetic setting and also in a non-diabetic setting, indicting the importance of RAGE and alternate RAGE ligands in the setting of collateral vessel growth.

  9. These findings demonstrate the role for RAGE-dependent IL-10 (zeige IL10 Antikörper) suppression as a key modulator of mortality from Gram-negative sepsis.

  10. HMGB1 (zeige HMGB1 Antikörper) promotes intraoral palatal wound healing through RAGE-dependent mechanisms.

Advanced Glycosylation End Product-Specific Receptor (AGER) Antigen-Profil

Beschreibung des Gens

The advanced glycosylation end product (AGE) receptor encoded by this gene is a member of the immunoglobulin superfamily of cell surface receptors. It is a multiligand receptor, and besides AGE, interacts with other molecules implicated in homeostasis, development, and inflammation, and certain diseases, such as diabetes and Alzheimer's disease. Many alternatively spliced transcript variants encoding different isoforms, as well as non-protein-coding variants, have been described for this gene (PMID:18089847).

Alternative names and synonyms associated with Advanced Glycosylation End Product-Specific Receptor (AGER)

  • advanced glycosylation end product-specific receptor (AGER) Antikörper
  • advanced glycosylation end product-specific receptor (Ager) Antikörper
  • advanced glycosylation end product-specific receptor (LOC100343142) Antikörper
  • AGER Antikörper
  • RAGE Antikörper

Bezeichner auf Proteinebene für AGER

advanced glycosylation end product-specific receptor , RAGE isoform NtRAGE-delta , RAGE isoform sRAGE-delta , RAGE/AGER , advanced glycation end product receptor , advanced glycosylation end product-specific receptor variant 1 , advanced glycosylation end product-specific receptor variant 3 , advanced glycosylation end product-specific receptor variant 4 , advanced glycosylation end product-specific receptor variant 5 , advanced glycosylation end product-specific receptor variant 6 , advanced glycosylation end product-specific receptor variant 7 , advanced glycosylation end product-specific receptor variant 8 , receptor for advanced glycosylation end products , advanced glycation end-products receptor , advanced glycosylation end product-specific receptor variant 2

GENE ID SPEZIES
462584 Pan troglodytes
177 Homo sapiens
403168 Canis lupus familiaris
396591 Sus scrofa
280986 Bos taurus
11596 Mus musculus
81722 Rattus norvegicus
100343142 Oryctolagus cuniculus
100726130 Cavia porcellus
101111586 Ovis aries
Ausgewählte Anbieter für anti-Advanced Glycosylation End Product-Specific Receptor (AGER) Antikörper
Haben Sie etwas anderes gesucht?